Mr. Jerry Lai reports

PANGENOMIC HEALTH ANNOUNCES CHANGES TO BOARD OF DIRECTORS AND MANAGEMENT, WARRANT UPDATE AND STOCK OPTION GRANTS

Pangenomic Health Inc. has appointed Manpreet Dhillon as a director of the company. Ms. Dhillon has over 20 years of international consulting experience specializing in implementing programs on economic empowerment, gender equality and stakeholder engagement for international non-governmental organizations and governments within the United Nations system. Ms. Dhillon is the founder of Veza Global, a Canadian organization working globally to provide solutions to support employers, human resource practitioners and organizations as a whole to effectively address diversity, equity, inclusion and belonging in the communities they serve. Ms. Dhillon has significant experience as a strategic leader with expertise in equity, diversity and inclusion programs, strategic planning, stakeholder engagement, brand development, and leadership coaching. Ms. Dhillon holds BBA and MA degrees.

The company also announces the resignation of Francisco Kent Carasquero as a director and chief financial officer of the company, effective immediately. Current financial consultant Tammy Gillis has assumed the position of CFO, a role that she previously served at the company. Ms. Gillis is a CPA and CMA with over 20 years experience in the public markets, and brings a comprehensive background in finance, reporting and regulatory requirements for junior exploration, manufacturing, biotechnology and technology industries.

The company is also pleased to announce that it has received approximately $731,000 in proceeds from the exercise of 4,300,464 share purchase warrants that were issued in May, 2024, and repriced to 17 cents per share as previously announced on Jan. 29, 2025. The proceeds will be used for general working capital purposes.

The company also announces that its board of directors has granted stock options representing a total of 1.35 million common shares to officers and directors of the company. These options were granted at an exercise price of $1.15, being the closing price on July 10, 2025, will vest in equal quarterly instalments over a one-year period and will expire on July 11, 2028. All options were granted pursuant to the company's stock option plan.

About Pangenomic Health Inc.

Pangenomic Health is a precision health company that has developed a self-care digital platform to deliver personalized, evidence-based information about natural treatments. The company's initial focus is to support mental health. Registered as a B.C. benefit company, Pangenomic Health has a mission to promote and improve the health and wellness of people and society by providing a technology platform that identifies plant-based solutions tailored to the health profile of each individual.

We seek Safe Harbor.